Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rozibafusp alfa - AstraZeneca

Next Previous
Drug Profile

Rozibafusp alfa - AstraZeneca

Alternative Names: AMG 570; Anti-B7RP-1mAb/BAFF; MEDI0700; Rozibafusp alfa

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antirheumatics; Bispecific antibodies; Immunoconjugates; Peptide drug conjugates
  • Mechanism of Action B cell activating factor inhibitors; B7-related protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 27 Apr 2023 Amgen terminates a phase II trial in Systemic lupus erythematosus (In the elderly, In adults) in Argentina, Germany, Canada, Hungary, Australia, Bulgaria, Czech Republic, France, Hong Kong, Italy, Japan, Mexico, Poland, Portugal, South Korea, Russia, Spain and in the US (SC) due to futility (before April 2023) (NCT04058028)
  • 15 Mar 2021 Viela Bio has been acquired and merged into Horizon Therapeutics plc
  • 05 Nov 2020 Pharmacokinetics, pharmacodynamics, immunogenicity, efficacy and adverse events data presented at 84th American College of Rheumatology and the 55th Association of Rheumatology Health Professionals ((ACR/ARP-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top